Kite Pharma disclosed the death of a cancer patient from brain swelling following treatment with the company's CAR-T therapy KTE-C19.
The FDA is currently reviewing an application submitted by Kite to approve KTE-C19 for patients with advanced non-Hodgkin lymphoma.
Last year, Juno Therapeutics was forced to discontinue development of JCAR015 following the deaths of five patients due to cerebral edema.
The FDA has not placed the Kite study on clinical hold.
Read the Street articlel